Jeffrey Trigilio - 30 Jun 2023 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Chief Financial Officer
Signature
/s/ Jacquelyn Sumer, Attorney-in-Fact
Issuer symbol
CGEM
Transactions as of
30 Jun 2023
Net transactions value
+$21,247
Form type
4
Filing time
05 Jul 2023, 21:27:47 UTC
Previous filing
21 Jun 2023
Next filing
13 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Award $21,247 +2,340 +2.7% $9.08 88,163 30 Jun 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of January 1, 2023 through June 30, 2023. This transaction is also exempt under Rule 16b-3(c).
F2 In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on January 1, 2023.